Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...

Novo Nordisk India and Emcure Pharma announced a strategic partnership on Monday to launch Poviztra (semaglutide injection 2.4 mg) in India. The collaboration aims to enhance the distribution and ...

Novo Nordisk India and Emcure Pharma have partnered to launch Poviztra (semaglutide 2.4 mg), a second brand of Wegovy®, in ...

The announcement comes as the Danish drugmaker struggles to grab significant market share in the Indian market before it ...

Wegovy, the blockbuster weight-loss drug launched in June, is set to get cheaper in India. Danish drugmaker Novo Nordisk has ...

The company's revenue from operations rose to Rs 2,269.8 crore, a 13.4 per cent increase from Rs 2,001.9 crore in Q2FY25 ...

Emcure reports Q2FY26 with 13.4% revenue growth at Rs. 2,270 crore & 25% PAT growth at Rs. 251 crore: Our Bureau, Bengaluru Tuesday, November 11, 2025, 15:50 Hrs [IST] Emcure Phar ...

Days after its rival Mounjaro emerged as the top-selling medicine in the country, Wegovy puts efforts to catch up ...

Novo Nordisk cuts Wegovy prices in India by up to 33% to boost access and counter Mounjaro’s growing market lead.

Emcure Pharmaceuticals reports Q2FY26 with 13% revenue growth and 25% PAT growth, driven by strong domestic and international performance.